Published in Respir Res on September 16, 2015
Infliximab therapy balances regulatory T cells, tumour necrosis factor receptor 2 (TNFR2) expression and soluble TNFR2 in sarcoidosis. Clin Exp Immunol (2016) 0.75
The Circulating Treg/Th17 Cell Ratio Is Correlated with Relapse and Treatment Response in Pulmonary Sarcoidosis Patients after Corticosteroid Withdrawal. PLoS One (2016) 0.75
CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells. J Exp Med (2006) 14.33
Functional delineation and differentiation dynamics of human CD4+ T cells expressing the FoxP3 transcription factor. Immunity (2009) 9.01
Statement on sarcoidosis. Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999. Am J Respir Crit Care Med (1999) 8.96
FOXP3+ regulatory T cells in the human immune system. Nat Rev Immunol (2010) 8.73
Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNFalpha therapy. J Exp Med (2004) 6.48
Mechanisms of impaired regulation by CD4(+)CD25(+)FOXP3(+) regulatory T cells in human autoimmune diseases. Nat Rev Immunol (2010) 3.69
Life and death in peripheral T cells. Nat Rev Immunol (2007) 3.67
Selective survival of naturally occurring human CD4+CD25+Foxp3+ regulatory T cells cultured with rapamycin. J Immunol (2007) 3.09
Th17 plasticity in human autoimmune arthritis is driven by the inflammatory environment. Proc Natl Acad Sci U S A (2010) 2.43
The immune paradox of sarcoidosis and regulatory T cells. J Exp Med (2006) 2.35
Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease. Gut (2002) 2.26
Global natural regulatory T cell depletion in active systemic lupus erythematosus. J Immunol (2005) 2.00
Homeostatic control of regulatory T cell diversity. Nat Rev Immunol (2014) 1.87
Functional defect of circulating regulatory CD4+ T cells in patients with Wegener's granulomatosis in remission. Arthritis Rheum (2007) 1.86
Patients with antineutrophil cytoplasmic antibody-associated vasculitis have defective Treg cell function exacerbated by the presence of a suppression-resistant effector cell population. Arthritis Rheum (2013) 1.70
Differential response of murine CD4+CD25+ and CD4+CD25- T cells to dexamethasone-induced cell death. Eur J Immunol (2004) 1.36
A functional polymorphism in fas (CD95/APO-1) gene promoter associated with systemic lupus erythematosus. J Rheumatol (2002) 1.26
Enrichment of CD4+ CD25high T cell population in patients with systemic lupus erythematosus treated with glucocorticoids. Ann Rheum Dis (2006) 1.17
Increased IL-17A expression in granulomas and in circulating memory T cells in sarcoidosis. Rheumatology (Oxford) (2011) 1.15
Inhaled vasoactive intestinal peptide exerts immunoregulatory effects in sarcoidosis. Am J Respir Crit Care Med (2010) 1.11
Immunologic response of sarcoidosis. Semin Respir Crit Care Med (2010) 1.10
FoxP3+ regulatory T cells suppress early stages of granuloma formation but have little impact on sarcoidosis lesions. Am J Pathol (2009) 1.05
Expression of tumor necrosis factor-receptor superfamily members by lung T lymphocytes in interstitial lung disease. Am J Respir Crit Care Med (1996) 1.03
Reversal of global CD4+ subset dysfunction is associated with spontaneous clinical resolution of pulmonary sarcoidosis. J Immunol (2013) 0.95
Apoptosis in the course of granulomatous inflammation in pulmonary sarcoidosis. Eur Respir J (1999) 0.95
Granuloma formation in pulmonary sarcoidosis. Front Immunol (2013) 0.93
Regulatory T cells with reduced repressor capacities are extensively amplified in pulmonary sarcoid lesions and sustain granuloma formation. Clin Immunol (2011) 0.91
Similar sensitivity of regulatory T cells towards CD95L-mediated apoptosis in patients with multiple sclerosis and healthy individuals. J Neurol Sci (2006) 0.91
Cellular activation in the immune response of sarcoidosis. Semin Respir Crit Care Med (2014) 0.88
Anti-TNF-α therapy improves Treg and suppresses Teff in patients with rheumatoid arthritis. Cell Immunol (2012) 0.88
Fas promoter polymorphisms: genetic predisposition to sarcoidosis in African-Americans. Tissue Antigens (2008) 0.84
Impaired function of regulatory T-cells in hypersensitivity pneumonitis. Eur Respir J (2010) 0.82
Medical therapy of sarcoidosis. Semin Respir Crit Care Med (2014) 0.82
Evidence for local dendritic cell activation in pulmonary sarcoidosis. Respir Res (2012) 0.81
High concentrations of soluble Fas ligand in bronchoalveolar lavage fluid of patients with pulmonary sarcoidosis. Respiration (2002) 0.80
Successful treatment of systemic de novo sarcoidosis with cyclosporine discontinuation and provision of rapamune after liver transplantation. Transpl Int (2011) 0.79
High CD95 expression of BAL lymphocytes predicts chronic course in patients with sarcoidosis. Respirology (2007) 0.77